Researchers based in Scandinavia and France examined almost 6,000 women who were prescribed either oseltamivir or zanamivir during pregnancy as well as almost 700,000 women who did not receive prescriptions during a pregnancy.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
The study shows that newly born infants do not face increased risks of adverse outcomes, including low birth weight, low Apgar score, preterm birth, stillbirth or birth defects. When the analyses were restricted to oseltamivir exposure only, the results remained the same.
However, the researchers noted that study has some limitations, such as the fact that they did not assess risks of adverse outcomes before 22 weeks of pregnancy.
More articles on healthcare quality:
10 most-read infection control stories in February
Mumps spreads to second NHL team: 2 Wild players isolated
Study: Care from non-physician clinicians equal to that of physicians in community health centers
